Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 301–400 of 777
Verrelli, C. M., & Rossa, F. D. (2021) · Mathematics · doi:10.3390/math9192414 · Cited by 10
“The reader is also referred to [19] for the latest study adopting a model with an age-dependent pre-pandemic contact matrix, reflecting the goal of a return to pre-pandemic routines once a vaccine is available, to compare five age-stratified vaccine prioritization strategies.”
BackgroundMethodBubar, K. M., Middleton, C. E., Bjorkman, K. K., Parker, R., & Larremore, D. B. (2022) · Nature Communications · doi:10.1038/s41467-022-30144-7 · Cited by 13
Self-citationChhetri, B., Vamsi, D. K. K., Prakash, D. B., Balasubramanian, S., & Sanjeevi, C. B. (2022) · Computational and Mathematical Biophysics · doi:10.1515/cmb-2022-0143 · Cited by 10
Joshi, K., Rumpler, É., Kennedy‐Shaffer, L., Bosan, R., & Lipsitch, M. (2023) · Vaccine · doi:10.1016/j.vaccine.2022.12.053 · Cited by 10
“If the goal instead is minimizing final size, targeting adults 20– 49 with an effective transmission-blocking vaccine minimizes cumulative incidence [14,15].”
Self-citationDavis, A., Eck, K. V., Copeland‐Linder, N., Phuong, K., & Belcher, H. M. E. (2023) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-023-05971-2 · Cited by 10
An Epidemic Model with Infection Age and Vaccination Age Structure
Webb, G. F., & Zhao, X. E. (2024) · Infectious Disease Reports · doi:10.3390/idr16010004 · Cited by 11
Negi, S. S., Sharma, N., & Başkonuş, H. M. (2024) · Gene · doi:10.1016/j.gene.2024.148586 · Cited by 11
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
Hladish, T. J., Pillai, A. N., Pearson, C. A. B., Toh, K. B., Tamayo, A. C., Stoltzfus, A., & Longini, I. M. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012128 · Cited by 10
“For pathogens that spread very quickly or frequently cause infections without a known exposure, vaccination strategies aim to vaccinate the most people, often preferring those with higher risk for severe outcomes [8, 9].”
Bouros, I., Hill, E. M., Keeling, M. J., Moore, S., & Thompson, R. N. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012309 · Cited by 13
“…strategies targeting specific subgroups of a population depends on associated heterogeneities (for example, the relative transmission rates and risks of severe infection outcomes associated with vulnerable and non-vulnerable individuals) and, crucially, on the objectives of policy makers [33].”
BackgroundSwitching vaccination among target groups to achieve improved long-lasting benefits
Li, R., Bjørnstad, O. N., & Stenseth, N. C. (2021) · Royal Society Open Science · doi:10.1098/rsos.210292 · Cited by 10
Rogozea, L. M., Sechel, G., Bularca, M. C., Coman, C., & Cocuz, M. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001400 · Cited by 10
Optimal Control Applied to Vaccination and Testing Policies for COVID-19
Olivares, A., & Staffetti, E. (2021) · Mathematics · doi:10.3390/math9233100 · Cited by 12
To Use Face Masks or Not After COVID-19 Vaccination? An Impact Analysis Using Mathematical Modeling
Kinyili, M., Munyakazi, J. B., & Mukhtar, A. Y. A. (2022) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2022.872284 · Cited by 10
Optimal vaccine roll-out strategies including social distancing for pandemics
Spiliotis, K., Koutsoumaris, C. C., Reppas, A. I., Papaxenopoulou, L. A., Starke, J., & Hatzikirou, H. (2022) · iScience · doi:10.1016/j.isci.2022.104575 · Cited by 10
“Moreover, the vaccination age stratification is another pressing problem (Bubar et al., 2021): older people show dramatically more severe SARS-CoV-2 courses of disease (Logunov et al., 2020, 2021), which demands their prioritization in the vaccine administration.”
InfluentialA data-validated temporary immunity model of COVID-19 spread in Michigan
Pell, B., Johnston, M. D., & Nelson, P. W. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022474 · Cited by 10
Optimal vaccination at high reproductive numbers: sharp transitions and counterintuitive allocations
Gavish, N., & Katriel, G. (2022) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2022.1525 · Cited by 11
Saha, A. K., Saha, S., & Podder, C. N. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.09.004 · Cited by 10
Physical activities pre- and post-COVID-19 vaccination and its implementations: A narrative review
Al-Mhanna, S. B., Ghazali, W. S. W., Maqsood, A., Mohamed, M., Ahmed, N., Afolabi, H. A., Mutalub, Y. B., Heboyan, A. G., & Zafar, M. S. (2023) · SAGE Open Medicine · doi:10.1177/20503121231158981 · Cited by 11
Yang, F., Tran, T. N.-A., Howerton, E., Boni, M. F., & Servadio, J. L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03025-z · Cited by 10
“This study contributes to current literature examining the benefits of vaccination coverage to manage COVID-19 [10, 67, 68] while also incorporating treatment coverage [56].”
SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings
Saluzzo, F., Mantegani, P., de Chaurand, V. P., Quaresima, V., Cugnata, F., Serio, C. D., Macé, A., de Vos, M., Sacks, J. A., & Cirillo, D. M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00250-21 · Cited by 10
“Finally, in a period of scarcity of vaccine doses, when several European countries, including Italy and France, are recommending a single dose of vaccine for individuals who were positive for SARS-CoV-2 in the previous 6 months, the tests with the highest specificity may be used to determine a prior infection and ther…”
BackgroundExpanding Capacity for Vaccines Against Covid-19 and Future Pandemics: A Review of Economic Issues
Athey, S. C., Castillo, J. C., Chaudhuri, E., Kremer, M. R., Gomes, A. S., & Snyder, C. (2022) · National Bureau of Economic Research · doi:10.3386/w30192 · Cited by 10
“According to one estimate (Bubar et al. 2021), 80% of Covid-19 mortality reduction would come from vaccinating the first 20% of a population.”
BackgroundRebound in epidemic control: how misaligned vaccination timing amplifies infection peaks
Castioni, P., Gómez, S., Granell, C., & Arenas, À. (2024) · npj Complexity · doi:10.1038/s44260-024-00020-0 · Cited by 11
“Thesamekindofoptimizationproblemhasbeenstudiedin relationtovaccination,forexampleinconnectiontoissuesofeconomical costs 21 , vaccination rates 22 , age prioritization 23 , boosters ’ distribution 13,24,25 and NPIs-vaccination synergy 26 .”
Plank, M. J., Hendy, S. C., Binny, R. N., Vattiato, G., Lustig, A. G., & Maclaren, O. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-25018-3 · Cited by 9
Validity of Markovian modeling for transient memory-dependent epidemic dynamics
Feng, M., Tian, L., Lai, Y., & Zhou, C. (2024) · Communications Physics · doi:10.1038/s42005-024-01578-w · Cited by 9
“S1 and Supplementary Notes 5 and 6 for a detailed analysis).”
BackgroundSocial learning in a network model of Covid-19
Davids, A., du Rand, G., Georg, C.-P., Koziol, T., & Schasfoort, J. (2023) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2023.07.010 · Cited by 9
A COVID-19 epidemic model predicting the effectiveness of vaccination
Webb, G. F. (2021) · Mathematics in Applied Sciences and Engineering · doi:10.5206/mase/13889 · Cited by 9
Barmpounakis, P., Demiris, N., Kontoyiannis, I., Pavlakis, G. N., & Sypsa, V. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263977 · Cited by 10
“Modelling studies broadly agree that, when vaccine supply is limited, prioritising the elderly is a necessary strategy to reduce COVID-19 mortality, whereas the prioritisation of younger individuals would have an impact on reducing transmission [13,14].”
BackgroundDelays, Masks, the Elderly, and Schools: First Covid-19 Wave in the Czech Republic
Berec, L., Smyčka, J., Levínský, R., Hromádková, E., Šoltés, M., Šlerka, J., Tuček, V., Trnka, J., Šmíd, M., Zajíček, M., et al. (2022) · Bulletin of Mathematical Biology · doi:10.1007/s11538-022-01031-5 · Cited by 9
“One type, exem- plified by Domenico et al. (2020), Ferguson et al. (2020), Kissler et al. (2020), Bubar et al. (2021) and Chang et al. (2021), is a mechanistic prospective model that aims at predicting a future course of epidemic given a set of alternative scenarios.”
BackgroundOptimal vaccine allocation for the control of sexually transmitted infections
Saldaña, F., Steindorf, V., Srivastav, A. K., Stollenwerk, N., & Aguiar, M. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01910-y · Cited by 9
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
Chatterjee, B., & Thakur, S. S. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1997601 · Cited by 13
“tion is one of the challenging tasks [16].”
BackgroundOptimization of vaccination for COVID-19 in the midst of a pandemic
Luo, Q., Weightman, R., McQuade, S. T., Díaz, M., Trélat, E., Barbour, W., Work, D. B., Samaranayake, S., & Piccoli, B. (2022) · Networks and Heterogeneous Media · doi:10.3934/nhm.2022016 · Cited by 9
“In [17], a compartmental model is used to address age-based questions about vaccination distribution.”
MethodCan a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?Preprint
Yu, H., Yang, J., Marziano, V., Deng, X., Guzzetta, G., Zhang, J., Trentini, F., Cai, J., Poletti, P., Zheng, W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-200069/v1 · Cited by 10
Could Vaccine Dose Stretching Reduce COVID-19 Deaths?
Więcek, W., Ahuja, A., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · National Bureau of Economic Research · doi:10.3386/w29018 · Cited by 13
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1227 · Cited by 8
Ali, A., Sun, M., & Ali, M. R. (2025) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2025.116284 · Cited by 8
Saldaña, J., & Scoglio, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06477-0 · Cited by 8
Cao, W., Zhu, J., Wang, X., Tong, X., Tian, Y., Dai, H., & Ma, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.921855 · Cited by 8
“Based on the characteristics of this COVID-19 pandemic, a series of extensions for the classical SIR model have been proposed, such as age-group separation (7, 8), the introduction of asymptomatic infections (9, 10), deaths (11), and immunity period (12), and the incorporation of graph-based spatial components (10, 13…”
MethodÍslind, A. S., Óskarsdóttir, M., Cot, C., Cacciapaglia, G., & Francesco Sannino, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-21055-0 · Cited by 8
Of Mice and Schoolchildren: A Conceptual History of Herd Immunity
Robertson, D. (2021) · American Journal of Public Health · doi:10.2105/ajph.2021.306264 · Cited by 8
Modeling Infectious Behaviors: The Need to Account for Behavioral Adaptation in COVID-19 Models.
Vardavas, R., de Lima, P. N., Davis, P. K., Parker, A. M., & Baker, L. (2021) · PubMed · Cited by 8
Eyal, N., Gheaus, A., Gosseries, A., Magalhaes, M., Ngosso, T., Steuwer, B., Tangcharoensathien, V., Trifan, I., & Williams, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac398 · Cited by 6
“muchmore commondeath fromCOVID-19 is amongolder people than among younger ones [7].”
BackgroundWu, H., Wang, K., & Xu, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.934891 · Cited by 10
“In reality, the other factor, such as the vaccine type (leaky vaccine or all-or-nothing vaccine), can also affect the switch pattern (16).”
BackgroundInfluentialPostinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2
Kršák, M., Harry, B. L., Palmer, B. E., & Franco‐Paredes, C. (2021) · Viral Immunology · doi:10.1089/vim.2021.0054 · Cited by 9
“Similar modeling with a modified list of parameters has recently been undertaken by a multi-institutional group of investigators (6).”
Jung, C., Excoffier, J.-B., Raphaël-Rousseau, M., Salaün-Penquer, N., Ortala, M., & CHOUAID, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263266 · Cited by 10
“The changes in these clinical risk factors can be explained by a change in the exposed population as the virus spread in the population between waves 1 and 2 and by the vaccination campaign for the elderly (� 75 years) and people “at risk” for the third wave [32].”
BackgroundDurmuş, V. (2022) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2022.292 · Cited by 7
Jovanović, R., Davidović, M., Lazović, I. M., Jovanović, M., & Jovašević-Stojanović, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126217 · Cited by 7
“Bubar and co-authors in their study [20] also adopted an age-based compartment SEIR model to investigate different vaccination strategies.”
BackgroundModeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine Administration
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · IEEE International Conference on Automation Science and Engineering (CASE) · doi:10.1109/case49439.2021.9551418 · Cited by 9
“For instance, in [14] the authors employ a mathematical model to compare five age-stratified prioritization strategies in order to reduce existing inequities in COVID-19 vaccine distribution.”
Selvaraj, P., Wagner, B. G., Chao, D. L., L’Azou, M., Breugelmans, J. G., Jackson, N., & Chang, S. T. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000053 · Cited by 8
“Previous modeling studies have indicated that prioritizing elderly adults for vaccination would yield the largest reductions in mortality [3, 4] given the steep gradient of mortality observed with age in China, Europe, and other countries [5, 6].”
Yang, X., Wang, S., Xing, Y., Li, L., Xu, R. Y. D., Friston, K. J., & Guo, Y. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009807 · Cited by 7
“Estimating such time-varying parameters from epidemiological observations (e.g., daily report of confirmed cases) is useful for nowcasting transmission [12], for retrospectively assessing intervention impacts and for developing vaccine strategies [6,13,14].”
Li, M., Zu, J., Zhang, Y., Ma, L., Shen, M., Li, Z., & Ji, F. (2022) · Virology Journal · doi:10.1186/s12985-022-01771-9 · Cited by 8
Dynamical intervention planning against COVID-19-like epidemics
Oliva, G., Schlueter, M., Munetomo, M., & Scala, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269830 · Cited by 7
Reyes, H., Diethelm-Varela, B., Méndez, C., Rebolledo-Zelada, D., Lillo-Dapremont, B., Muñoz, S. R., Bueno, S., González, P., & Kalergis, A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.815036 · Cited by 7
“3-fold decrease in the rate of infection in the group that received a booster, as compared to those individuals vaccinated with only two doses (41, 42).”
ResultExploring a COVID‐19 Endemic Scenario: High‐Resolution Agent‐Based Modeling of Multiple Variants
Truszkowska, A., Zino, L., Butail, S., Caroppo, E., Jiang, Z., Rizzo, A., & Porfiri, M. (2022) · Advanced Theory and Simulations · doi:10.1002/adts.202200481 · Cited by 8
Lessons Learned from a Global Perspective of Coronavirus Disease-2019
Kaul, V., Chahal, J., Schrarstzhaupt, I. N., Geduld, H. I., Shen, Y., Cecconi, M., Siqueira, A. M., Markoski, M. M., & Kawano-Dourado, L. B. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.020 · Cited by 8
“) As we have learned from the pandemic, agebased vaccine distribution strategies were crucial for mortality reduction.(86,87) Countries globally adopted this recommendation prioritizing olderage individuals and health care workers.”
Evaluating vaccine allocation strategies using simulation-assisted causal modeling
Kekić, A., Dehning, J., Gresele, L., von Kügelgen, J., Priesemann, V., & Schölkopf, B. (2023) · Patterns · doi:10.1016/j.patter.2023.100739 · Cited by 11
“However, in these studies, such differences in contribution to spread stem from assumptions on the contact matrix 17,33,35 or prior knowledge of susceptibility, 17,33,34 whereas in our method, we estimate the age-dependent reproduction numbers directly from infection data.”
BackgroundMethodResultCarretero, R. G., Gómez, O. V., Ordoñez-Garcia, M., Garrido-Peño, N., Gil-Prieto, R., & de Miguel, Á. G. (2023) · Viruses · doi:10.3390/v15071616 · Cited by 9
“Some recent publications have focused on choosing the best vaccination strategy based on certain criteria [46,47].”
BackgroundHow enlightened self-interest guided global vaccine sharing benefits all: A modeling study
Han, Z., Chen, L., Hao, Q., He, Q., Budeski, K., Jin, D., Xu, F., Tang, K., & Li, Y. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06038 · Cited by 7
“Recent studies focused on improving the effectiveness [16-18] and equity [19-23] of the domestic distribution of vaccines, but have been incapable of modeling the national interests of sovereign countries and scaling up to global vaccine distribution [11,24].”
BackgroundMa, Z., & Rennert, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-57488-y · Cited by 7
Dashtbali, M., & Mirzaie, M. (2024) · Journal of the Franklin Institute · doi:10.1016/j.jfranklin.2024.106994 · Cited by 7
Garcia, Y. H., Díaz‐Infante, S., & Minjárez‐Sosa, J. A. (2025) · Decision Analytics Journal · doi:10.1016/j.dajour.2024.100543 · Cited by 7
Vaccination Dynamics of Age-Structured Populations in Higher-Order Social Networks
Nie, Y., Lin, T., Liu, Y., & Wang, W. (2025) · IEEE Transactions on Systems Man and Cybernetics Systems · doi:10.1109/tsmc.2025.3559885 · Cited by 7
“Comparing five age-stratified prioritization strategies, Bubar et al. [16] found that prioritizing COVID-19 vaccination for adults aged 20–49 could minimize the cumulative incidence.”
Hunziker, P. (2021) · Precision Nanomedicine · doi:10.33218/001c.26101 · Cited by 7
Determination of critical decision points for COVID-19 measures in Japan
Kim, J., Matsunami, K., Okamura, K., Badr, S., & Sugiyama, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-95617-z · Cited by 7
The role of childrens’ vaccination for COVID-19—Pareto-optimal allocations of vaccines
Gavish, N., & Katriel, G. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009872 · Cited by 8
“We follow the procedure as in [16] to adapt the matrices into 10-year increments.”
InfluentialTomaiuolo, R., Restelli, U., Faggiano, F. C., Resta, C. D., Albitar‐Nehme, S., Giuliani, F., Derrico, P., Ricciardi, W., Banfi, G., & Ritrovato, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0262 · Cited by 7
“Then, the two vaccination strategies were evaluated by the SEIR epidemiological model (Figure 2) [11], of which the source codes areprovidedandexecutablethroughthefreestatisticalsoftwareR[12].”
MethodRapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants
Cheng, H. L., Lim, S. M., Jia, H., Chen, M. W., Ng, S. Y., Gao, X., Somani, J., Sengupta, S., Tay, D. M. Y., Chua, P. W. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02257-22 · Cited by 7
Kappes, A., Zohny, H., Savulescu, J., Singh, I., Sinnott-Armstrong, W. P., & Wilkinson, D. J. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062561 · Cited by 7
The Trade-off Between Prioritization and Vaccination Speed Depends on Mitigation Measures
Agarwal, N., Komo, A., Patel, C., Pathak, P. A., & Ünver, M. U. (2021) · National Bureau of Economic Research · doi:10.3386/w28519 · Cited by 8
Strategies to Mitigate COVID-19 Resurgence Assuming Immunity Waning: A Study for Karnataka, IndiaPreprint
Adiga, A., Athreya, S., Lewis, B. L., MARATHE, M. V., Rathod, N., Sundaresan, R., Swarup, S., Venkatramanan, S., & Yasodharan, S. (2021) · medRxiv · doi:10.1101/2021.05.26.21257836 · Cited by 8
“Finally, the current vaccination campaign does not utilise the serostatus of individuals as in [8], and so some proportion of the capacity is used up for those already immune.”
BackgroundOptimal Vaccine Allocation for Pandemic StabilizationPreprint
Ma, Q., Liu, Y., & Olshevsky, A. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2109.04612 · Cited by 7
“Then we compare the proposed policy with the five age-stratified policies provided in [11].”
BackgroundMethodInfluentialChin, T., Feehan, D. M., Buckee, C. O., & Mahmud, A. S. (2021) · medRxiv · doi:10.1101/2021.09.25.21264082 · Cited by 8
“…2020; Enns et al., 2020), based on the POLYMOD study in Europe (Mossong et al., 2008), or on synthetic (modeled) contact rates (Davies et al., 2020; Bubar et al., 2021; Prem et al., 2020; Larremore et al., 2021) based on POLYMOD and country-specific socio-demographic data (Prem, Cook, & Jit, 2017;…”
MethodBojórquez, I., Rojas-Botero, M. L., Marín, D. P., Riveros, M. A., Roa, A. Y., & Fernández-Niño, J. A. (2023) · Journal of Migration and Health · doi:10.1016/j.jmh.2023.100207 · Cited by 6
“…maximize the socio-health impacts of the vaccines in the face of an initial global shortage (especially critical in low-and middle-income countries), this process was even more sensitive, since it was not clear when the non-prioritized groups would be able to receive vaccines (Bubar et al., 2021).”
BackgroundEspinosa, O., Mora, L., Sanabria, C., Ramos, A., Rincón, D., Bejarano, V., Rodríguez, J., Barrera, N., Álvarez, C., Cortés, J. A., et al. (2024) · Systematic Reviews · doi:10.1186/s13643-023-02411-1 · Cited by 7
Bhattacharya, P., Machi, D., Chen, J., Hoops, S., Lewis, B. L., Mortveit, H., Venkatramanan, S., Wilson, M., Marathe, A., Porebski, P. J., et al. (2024) · Journal of Parallel and Distributed Computing · doi:10.1016/j.jpdc.2024.104899 · Cited by 6
Vaccination and Collective Action Under Social Norms
Morsky, B. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01436-y · Cited by 11
“It is well-established that heterogeneity in contact patterns (Bansal et al. 2007) and age structure (Keeling 1999; Bubar et al. 2021) can dramatically affect infectious disease dynamics and vaccination distribution strategies.”
COVID-19 Vaccination Priority Evaluation
Dujmovic, J. J., & Tomasevich, D. (2021) · Lecture notes in networks and systems · doi:10.1007/978-3-030-82099-2_10 · Cited by 6
Vignals, C., Dick, D. W., Thiébaut, R., Wittkop, L., Prague, M., & Heffernan, J. M. (2021) · COVID · doi:10.3390/covid1020041 · Cited by 6
Epidemic Vulnerability Index for Effective Vaccine Distribution Against Pandemic
Lee, H., Kang, M., Kim, D., Seo, D., & Li, Y. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3198365 · Cited by 6
“Bubar et al. [12] suggested five vaccination distribution schemes analyzed based on the standard of age stratification and showed the coinciding result efficacy after vaccination simulations with SEIR [21] (Susceptible, Exposed, Infectious, Recovered) model.”
BackgroundMethodOptimal vaccination control for COVID-19 in a metapopulation model: a case of the Philippines
Caga-anan, R. L., Macalisang, J. M., Dalisay, J. L., Raza, M. N., Martinez, J. G., & Arcede, J. P. (2023) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2023.1154634 · Cited by 6
Using Reinforcement Learning for Optimizing COVID-19 Vaccine Distribution Strategies
Damaševičius, R., Maskeliūnas, R., & Misra, S. (2023) · Springer optimization and its applications · doi:10.1007/978-3-031-33183-1_10 · Cited by 7
Tradigo, G., Das, J. K., Vizza, P., Roy, S., Guzzi, P. H., & Veltri, P. (2023) · Vaccines · doi:10.3390/vaccines11091496 · Cited by 6
“However, not withstanding the rapid response to COVID-19, it became clear that it was impossible to satisfy the demand for vaccines and hence the need for prioritization strategies [7].”
BackgroundLiu, L., Wang, X., & Li, Y. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023925 · Cited by 6
“This has posed a significant threat to the well-being of humans, giving rise to major public health challenges and economic crises [1,2].”
BackgroundLiu, T., Yin, X., Liu, Q., & Hounye, A. H. (2023) · Alexandria Engineering Journal · doi:10.1016/j.aej.2023.11.068 · Cited by 6
Montagud, A. C., Vicente-Alcalde, N., Bravo, E. M. G., Sánchez, J. A. H., Penadés, E. M., Egoavil, C. M., Chavarría-Alarcón, E., Caballero, P., & Tuells, J. (2023) · PubMed Central · Cited by 6
Inferring COVID-19 testing and vaccination behavior from New Jersey testing data
Freedman, A. S., Sheen, J. K., Tsai, S., Yao, J., Lifshitz, E. I., Adinaro, D., Levin, S. A., Grenfell, B. T., & Metcalf, C. J. E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314357121 · Cited by 6
Mendes, D., Krishnan, S. M., O’Brien, E., Padgett, T., Harrison, C., Strain, W. D., Manca, A., Ustianowski, A., Butfield, R., Hamson, E., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00965-8 · Cited by 7
“Expanding vaccine eligibility criteria to all adults and children over the age of 12 may indirectly protect those of advanced age and at risk of severe complications from COVID-19, which aligns with previous studies [48, 49].”
ResultArdjmand, E., Fallahtafti, A., Yazdani, E., Mahmoodi, A., & Young, W. A. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.112322 · Cited by 6
On the role of statisticians and modelers in responding to AIDS and COVID‐19
Jewell, B. L., & Jewell, N. P. (2021) · Statistics in Medicine · doi:10.1002/sim.8943 · Cited by 6
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
Eyal, N., & Gerhard, T. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-107109 · Cited by 6
Public Views on Priority Groups for COVID-19 Vaccination: A Survey from Iran
Moradi, N., Heydari, S. T., Zarei, L., Arabloo, J., Rezapour, A., Meshkani, Z. S., & Lankarani, K. B. (2021) · Shiraz E-Medical Journal · doi:10.5812/semj.113359 · Cited by 6
Choi, W., & Shim, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132813 · Cited by 6
Sentinel node approach to monitoring online COVID-19 misinformation
Osborne, M., Malloy, S. S., Nisbet, E. C., Bond, R. M., & Tien, J. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-12450-8 · Cited by 8
“The significant potential for misinformation to drive behavioral change such as vaccine hesitancy [6,7] underscores the importance of identifying and mitigating COVID-19 misinformation.”
BackgroundA Mathematical Study of COVID-19 Spread by Vaccination Status in Virginia
Johnston, M. D., Pell, B., & Nelson, P. W. (2022) · Applied Sciences · doi:10.3390/app12031723 · Cited by 6
Kobayashi, T., & Nishiura, H. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022350 · Cited by 7
Assessing COVID-19 vaccination strategies in varied demographics using an individual-based model
Ben-Zuk, N., Daon, Y., Sasson, A., Ben-Adi, D., Huppert, A., Nevo, D., & Obolski, U. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966756 · Cited by 8
“Indeed, this has been 329 demonstrated in theoretical studies (15) and was the strategy of choice in many countries (44), 330 following the finding that older individuals have higher chances of developing severe COVID-19 331 given infection.”
BackgroundMethodBaldia, P. H., Wernly, B., Flaatten, H. K., Fjølner, J., Artigas, A., Pinto, B. B., Schefold, J. C., Kelm, M., Beil, M., Bruno, R. R., et al. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03709-w · Cited by 7
“In response to the eminently high vulnerability of old and frail patients, many countries chose to prioritize this vulnerable group in their vaccination programs to protect them from a likely fatal outcome [8].”
BackgroundKataria, S., Phogat, R., Sharma, P., Deswal, V., Alam, S., Singh, M. K., Kumar, K., Gupta, V., Singh, P., Dutt, R., et al. (2023) · The National Medical Journal of India · doi:10.25259/nmji_345_21 · Cited by 6
Salcedo-Varela, G. A., Peñuñuri, F., González‐Sánchez, D., & Díaz‐Infante, S. (2023) · Optimal Control Applications and Methods · doi:10.1002/oca.3032 · Cited by 6
“10 At the date of writing this introduction, we perceive the recent References 11-14 as relevant contributions of models related with applications of optimal control theory.”
ResultInfluentialYuan, J., Lam, W., Xiao, J., Cowling, B. J., Ni, M. Y., Dong, M., & Liao, Q. (2023) · Psychology and Health · doi:10.1080/08870446.2023.2239279 · Cited by 6
“While vaccinating the older population is crucial for minimizing mortality due to COVID-19 (Bubar et al., 2021), vaccinating the younger population against COVID-19 is important for blocking the transmission of SARS-CoV-2 in the community (Matrajt et al., 2020).”
Adimulam, T., Arumugam, T., Naidoo, A., Naidoo, K., & Ramsuran, V. (2023) · Genes · doi:10.3390/genes14091798 · Cited by 6
“Bubar et al. (2021) suggested the use of a strategy using age and serostatus to prioritize vaccine roll-out and prioritization [74].”
Method
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.